Literature DB >> 29669768

Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis.

Ahmed El-Solia1, Khalid Al-Otaibi2, Abdullah K Ai-Hwiesh3.   

Abstract

Hydroxychloroquine (HCQ) is a commonly used drug for the treatment of systemic lupus erythematosus (SLE). Renal involvement is common in SLE. We present a 25-year-old woman with lupus nephritis on peritoneal dialysis whose lupus was quite silent for almost three years, and secondary to HCQ she developed severe hypoglycaemic episodes, which were completely resolved after stopping HCQ. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  dialysis; drugs: musculoskeletal and joint diseases; renal system; systemic lupus erythematosus; unwanted effects/adverse reactions

Mesh：

Substances：

Year:  2018        PMID： 29669768      PMCID： PMC5911099          DOI： 10.1136/bcr-2017-223639

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  16 in total

1.  Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA.

Authors:  D U Cansu; C Korkmaz
Journal:  Rheumatology (Oxford)       Date:  2008-01-25       Impact factor: 7.580

2.  Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease.

Authors:  Monique Bethel; Frances M Yang; Shuang Li; N Stanley Nahman; Alyce M Oliver; Wambui Machua; Laura D Carbone
Journal:  J Investig Med       Date:  2016-02-19       Impact factor: 2.895

3.  Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Sara Kaprove Penn; Amy H Kao; Laura L Schott; Jennifer R Elliott; Frederico G S Toledo; Lewis Kuller; Susan Manzi; Mary Chester M Wasko
Journal:  J Rheumatol       Date:  2010-05-01       Impact factor: 4.666

4.  Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.

Authors:  Yi-Ming Chen; Ching-Heng Lin; Tsuo-Hung Lan; Hsin-Hua Chen; Shih-Ni Chang; Yi-Hsing Chen; Jun-Sing Wang; Wei-Ting Hung; Joung-Liang Lan; Der-Yuan Chen
Journal:  Rheumatology (Oxford)       Date:  2015-01-12       Impact factor: 7.580

5.  Hydroxychloroquine: a diabetic drug in disguise?

Authors:  Lydia Kang; Ted R Mikuls; James R O'Dell
Journal:  BMJ Case Rep       Date:  2009-03-02

6.  Serum level of amylase and lipase in various stages of chronic renal insufficiency.

Authors:  Chaw-Fung Jiang; Kam-Wing Ng; So-Wan Tan; Chiang-Shui Wu; Hsueh-Chuan Chen; Chung-Ting Liang; Yone-Hwe Chen
Journal:  Zhonghua Yi Xue Za Zhi (Taipei)       Date:  2002-02

7.  The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial.

Authors:  Hertzel C Gerstein; Kevin E Thorpe; D Wayne Taylor; R Brian Haynes
Journal:  Diabetes Res Clin Pract       Date:  2002-03       Impact factor: 5.602

Review 8.  Hydroxychloroquine neuromyotoxicity.

Authors:  M Stein; M J Bell; L C Ang
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

9.  Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.

Authors:  Mary Chester M Wasko; Helen B Hubert; Vijaya Bharathi Lingala; Jennifer R Elliott; Michael E Luggen; James F Fries; Michael M Ward
Journal:  JAMA       Date:  2007-07-11       Impact factor: 56.272

10.  Pancreatic enzymes in chronic renal failure.

Authors:  V L Royse; D M Jensen; H L Corwin
Journal:  Arch Intern Med       Date:  1987-03
View more
  6 in total

Review 1.  Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

2.  Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations.

Authors:  Jingchen Zhai; Beihong Ji; Lianjin Cai; Shuhan Liu; Yuchen Sun; Junmei Wang
Journal:  J Pers Med       Date:  2022-05-14

3.  System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India.

Authors:  Praveen Kumar-M; Ritin Mohindra; Ashish Bhalla; Nusrat Shafiq; Vikas Suri; Deepa Kumari; Avaneesh Kumar Pandey; Ankur Gupta; Parul Chawla Gupta; Amol Patil; Ashish Kumar Kakkar; Samir Malhotra
Journal:  Expert Rev Anti Infect Ther       Date:  2021-04-15       Impact factor: 5.091

Review 4.  Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.

Authors:  Alina Dima; Ciprian Jurcut; François Chasset; Renaud Felten; Laurent Arnaud
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-02-14       Impact factor: 5.346

Review 5.  Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic.

Authors:  Marco Infante; Camillo Ricordi; Andrea Fabbri
Journal:  J Diabetes       Date:  2020-06-11       Impact factor: 4.530

6.  Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection.

Authors:  Philippe Giaime; Maxime Guenoun; Nathalie Pedinielli; Hervé Narbonne; Jean-Philippe Bergounioux; Caroline Solas; Romain Guilhaumou; Jérôme Sampol; Jacques Ollier; Hélène Sichez; Marianne Serveaux; Flora Brunner; Stanislas Bataille
Journal:  Nephrol Dial Transplant       Date:  2020-08-01       Impact factor: 5.992
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.